peterschreiber.media Truist Securities raised its rating of Evolent Health (NYSE:EVH) to buy, citing the company’s rate increases to offset \"elevated disease prevalence and acuity.\" “We always believed in the company’s ability to grow its topline, but now have improved confidence in its ability to expand margins in the coming years,” the analysts wrote in their note. Truist added that due to “improved visibility”, it now finds the shares “appealing at current valuations.” Truist raised its price target for the stock to $33 from $28.